Current approaches to the development of vaccines effective against parainfluenza viruses
- PMID: 2844427
- PMCID: PMC2491123
Current approaches to the development of vaccines effective against parainfluenza viruses
Abstract
Infection of infants and children with parainfluenza viruses can lead to serious lower respiratory tract disease. In order to review new information on the genetic organization, epidemiology, and immunobiology of these viruses and of respiratory syncytial virus, WHO, in conjunction with the National Institute of Allergy and Infectious Diseases, held a workshop in Bethesda, MD, USA, 4-5 May 1987. New data on the immunobiology and epidemiology of human parainfluenza 3 virus were presented that should facilitate the development of a vaccine against this pathogen.
Similar articles
-
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.Bull World Health Organ. 1997;75(4):307-13. Bull World Health Organ. 1997. PMID: 9342889 Free PMC article.
-
Studies on the epidemiology of child infections. 3. Parainfluenza viruses (types 1-4) and respiratory syncytial virus infections.Microbios. 1992;72(290):55-63. Microbios. 1992. PMID: 1335108
-
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1. Pediatr Infect Dis J. 2009. PMID: 19483659 Clinical Trial.
-
Current status of vaccines for parainfluenza virus infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Pediatr Infect Dis J. 2008. PMID: 18820572 Review.
-
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.J Clin Invest. 2002 Jul;110(1):21-7. doi: 10.1172/JCI16077. J Clin Invest. 2002. PMID: 12093883 Free PMC article. Review. No abstract available.
Cited by
-
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.Virology. 2010 Oct 10;406(1):65-79. doi: 10.1016/j.virol.2010.07.011. Epub 2010 Jul 27. Virology. 2010. PMID: 20667570 Free PMC article.
-
Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.Vaccine. 2010 Mar 24;28(15):2788-98. doi: 10.1016/j.vaccine.2010.01.050. Epub 2010 Feb 20. Vaccine. 2010. PMID: 20139039 Free PMC article.
-
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.J Virol. 2011 Apr;85(8):4007-19. doi: 10.1128/JVI.02542-10. Epub 2011 Feb 2. J Virol. 2011. PMID: 21289116 Free PMC article.
-
Genotype replacement of the human parainfluenza virus type 2 in Croatia between 2011 and 2017 - the role of neutralising antibodies.Epidemiol Infect. 2018 Aug;146(11):1372-1383. doi: 10.1017/S0950268818001693. Epub 2018 Jun 18. Epidemiol Infect. 2018. PMID: 29909804 Free PMC article.
-
Progress in the development of human parainfluenza virus vaccines.Expert Rev Respir Med. 2011 Aug;5(4):515-26. doi: 10.1586/ers.11.32. Expert Rev Respir Med. 2011. PMID: 21859271 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources